Transcriptional targeting in cancer gene therapy

Journal of Biomedicine and Biotechnology

Volumn 2003, Issue 2, 2003, Pages 110-137

  Robson, Tracy ^a   Hirst, David G ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; CARCINOEMBRYONIC ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENOLASE; GLIAL FIBRILLARY ACIDIC PROTEIN; MIDKINE; MONOPHENOL MONOOXYGENASE; MUCIN 1; MYELIN BASIC PROTEIN; OSTEOCALCIN; PROBASIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEOLIPID PROTEIN; RETROVIRUS VECTOR; SURFACTANT PROTEIN B; SYNAPSIN I; THYROGLOBULIN; TISSUE KALLIKREIN; TRANSCRIPTION FACTOR E2F; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; GENE CONTROL; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSCRIPTION; HERPES SIMPLEX VIRUS VECTOR; HUMAN; METASTASIS; NONHUMAN; ONCOGENE NEU; PROMOTER REGION; REVIEW; TRANSGENE; TUMOR CELL;

ADENOVIRIDAE; ALPHAVIRUS; HERPES; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0038347805     PISSN: 11107243     EISSN: None     Source Type: Journal    
DOI: 10.1155/S1110724303209074     Document Type: Review

References (277)

1. Maron DJ, Choi EA, Spitz FR. Gene therapy of metastatic disease: progress and prospects. Surg Oncol Clin N Am. 2001;10(2):449-460.
2. Brown MD, Schatzlein AG, Uchegbu IF. Gene delivery with synthetic (non viral) carriers. Int I Pharm. 2001;229(1-2):1-21.
3. McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer. 2001;1(2):130-141.
4. Barnett BG, Crews CJ, Douglas JT. Targeted adenoviral vectors. Biochim Biophys Acta. 2002;1575(1-3):1-14.
5. Vile RG, Hart IR. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 1993;53(5):962-967.
6. Vile RG, Hart IR. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res. 1993;53(17):3860-3864.
7. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 1994;54(23):6228-6234.
8. Vile R, Miller N, Chernajovsky Y, Hart I. A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Ther. 1994;1(5):307-316.
9. Diaz RM, Eisen T, Hart IR, Vile RG. Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma. J Virol. 1998;72(1):789-795.
10. Cao G, Zhang X, He X, Chen Q, Qi Z. A safe, effective in vivo gene therapy for melanoma using tyrosinase promoter-driven cytosine deaminase gene. In Vivo. 1999;13(2):181-187.
11. Szala S, Missol E, Sochanik A, Strozyk M. The use of cationic liposomes DC-CHOL/DOPE and DDAB/DOPE for direct transfer of Escherichia coli cytosine deaminase gene into growing melanoma tumors. Gene Ther. 1996;3 (11):1026-1031.
12. Siders WM, Halloran PJ, Fenton RG. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res. 1996;56(24):5638-5646.
13. Jerome V, Muller R. Tissue-specific, cell cycle-regulated chimeric transcription factors for the targeting of gene expression to tumor cells. Hum Gene Ther. 1998;9(18):2653-2659.
14. Emiliusen L, Gough M, Bateman A, et al. A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporatesan immunostimulatory component. Gene Ther. 2001;8(13):987-998.
15. Nahde T, Muller K, Fahr A, Muller R, Brusselbach S. Combined transductional and transcriptional targeting of melanoma cells by artificial virus-like particles. J Gene Med. 2001;3(4):353-361.
16. Vile RG, Hart IR. Targeting of cytokine gene expression to malignant melanoma cells using tissue specific promoter sequences. Ann Oncol. 1994;5 (suppl 4):59-65.
17. Hart IR. Tissue specific promoters in targeting systemically delivered gene therapy. Semin Oncol. 1996;23(1):154-158.
18. Bazzoni F, Regalia E. Triggering of antitumor activity through melanoma-specific transduction of a constitutively active tumor necrosis factor (TNF) R1 chimeric receptor in the absence of TNF-alpha. Cancer Res. 2001;61(3):1050-1057.
19. Pang S, Taneja S, Dardashti K, et al. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene Ther. 1995;6(11):1417-1426.
20. Lee CH, Liu M, Sie KL, Lee MS. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer. Anticancer Res. 1996;16(4A):1805-1811.
21. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57(13):2559-2563.
22. Gotoh A, Ko SC, Shirakawa T, et al. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J Urol. 1998;160(1):220-229.
23. Wu L, Matherly J, Smallwood A, et al. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther. 2001;8(18):1416-1426.
24. Spitzweg C, Zhang S, Bergert ER, et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res. 1999;59(9):2136-2141.
25. Latham JP, Searle PF, Mautner V, James ND. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res. 2000;60(2):334-341.
26. Yu D, Chen D, Chiu C, Razmazma B, Chow YH, Pang S. Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther. 2001;8(9):628-635.
27. Suzuki S, Tadakuma T, Kunitomi M, et al. Liposome-mediated gene therapy using HSVTK/ganciclovir under the control of human PSA promoter in prostate cancer cells. Urol Int. 2001;67(3):216-223.
28. Steiner MS, Zhang Y, Carraher J, Lu Y. In vivo expression of prostate-specific adenoviral vectors in a canine model. Cancer Gene Ther. 1999;6(5):456-464.
29. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994;54(20):5474-5478.
30. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res. 2000;60(22):6526-6530.
31. Gong MC, Chang SS, Watt F, et al. Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. Mol Urol. 2000;4(3):217-222; discussion 223.
32. Suzuki S, Tadakuma T, Asano T, Hayakawa M. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations. Cancer Res. 2001;61(4):1276-1279.
33. Zhang S, Gu J, Yang NS, et al. Relative promoter strengths in four human prostate cancer cell lines evaluated by particle bombardment-mediated gene transfer. Prostate. 2002;51(4):286-292.
34. O'Keefe DS, Uchida A, Bacich DJ, et al. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate. 2000;45(2):149-157.
35. Uchida A, O'Keefe DS, Bacich DJ, Molloy PL, Heston WD. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy. Urology. 2001;58(2)suppl 1:132-139.
36. Watt F, Martorana A, Brookes DE, et al. A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics. 2001;73(3):243-254.
37. Yu DC, Sakamoto GT, Henderson DR. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 1999;59(7):1498-1504.
38. Xie X, Zhao X, Liu Y, et al. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter. Hum Gene Ther. 2001;12(5):549-561.
39. Zhang J, Thomas TZ, Kasper S, Matusik RJ. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology. 2000;141(12):4698-4710.
40. Lowe SL, Rubinchik S, Honda T, McDonnell TJ, Dong JY, Norris JS. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells. Gene Ther. 2001;8(18):1363-1371.
41. Martiniello-Wilks R, Tsatralis T, Russell P, et al. Transcription-targeted gene therapy for androgen-independent prostate cancer. Cancer Gene Ther. 2002;9(5):443-452.
42. van der Poel HG, McCadden J, Verhaegh GW, et al. A novel method for the determination of basal gene expression of tissue-specific promoters: an analysis of prostate-specific promoters. Cancer Gene Ther. 2001;8(12):927-935.
43. Miyao Y, Shimizu K, Moriuchi S, et al. Selective expression of foreign genes in glioma cells: use of the mouse myelin basic protein gene promoter to direct toxic gene expression. J Neurosci Res. 1993;36(4):472-479.
44. Miyao Y, Shimizu K, Tamura M, et al. Usefulness of a mouse myelin basic protein promoter for gene therapy of malignant glioma: myelin basic protein promoter is strongly active in human malignant glioma cells. Jpn J Cancer Res. 1997;88(7):678-686.
45. Vandier D, Rixe O, Brenner M, Gouyette A, Besnard F. Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simplex virus-thymidine kinase gene. Cancer Res. 1998;58(20):4577-4580.
46. Vandier D, Rixe O, Besnard F, et al. Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter. Cancer Gene Ther. 2000;7(8):1120-1126.
47. McKie EA, Graham DI, Brown SM. Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector - potential glioblastoma targeting. Gene Ther. 1998;5(4):440-450.
48. Morelli AE, Larregina AT, Smith-Arica J, et al. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity. J Gen Virol. 1999;80(pt 3):571-583.
49. Chen J, Bezdek T, Chang J, et al. A glial-specific, repressible, adenovirus vector for brain tumor gene therapy. Cancer Res. 1998;58(16):3504-3507.
50. Shi N, Zhang Y, Zhu C, Boado RJ, Pardridge WM. Brain-specific expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci USA. 2001;98(22):12754-12759.
51. Glenn GM, Chatterjee S. Generation of adenoviruses encoding the herpes simplex virus vhs gene: a novel strategy to generate adenoviruses expressing genes toxic to producer cells. Cancer Gene Ther. 2001;8(8):566-572.
52. Shinoura N, Ohashi M, Yoshida Y, et al. Adenovirus-mediated overexpression of Fas induces apoptosis of gliomas. Cancer Gene Ther. 2000;7(2):224-232.
53. Shinoura N, Saito K, Yoshida Y, et al. Adenovirus-mediated transfer of bax with caspase-8 controlled by myelin basic protein promoter exerts an enhanced cytotoxic effect in gliomas. Cancer Gene Ther. 2000;7(5):739-748.
54. Shinoura N, Koike H, Furitu T, et al. Adenovirus-mediated transfer of caspase-8 augments cell death in gliomas: implication for gene therapy. Hum Gene Ther. 2000;11(8):1123-1137.
55. Martin V, Cortes ML, de Felipe P, Farsetti A, Calcaterra NB, Izquierdo M. Cancer gene therapy by thyroid hormone-mediated expression of toxin genes. Cancer Res. 2000;60(12):3218-3224.
56. Tanaka M, Inase N, Miyake S, Yoshizawa Y. Neuron specific enolase promoter for suicide gene therapy in small cell lung carcinoma. Anticancer Res. 2001;21(1A):291-294.
57. Ralph GS, Bienemann A, Harding TC, Hopton M, Henley J, Uney JB. Targeting of tetracycline-regulatable transgene expression specifically to neuronal and glial cell populations using adenoviral vectors. Neuroreport. 2000;11(9):2051-2055.
58. Glover CP, Bienemann AS, Heywood DJ, Cosgrave AS, Uney JB. Adenoviral-mediated, high-level, cell-specific transgene expression: a SYN1-WPRE cassette mediates increased transgene expression with no loss of neuron specificity. Mol Ther. 2002;5(pt 1):509-516.
59. Narita M, Bahar R, Hatano M, et al. Tissue-specific expression of a suicide gene for selective killing of neuroblastoma cells using a promoter region of the NCX gene. Cancer Gene Ther. 2001;8(12):997-1002.
60. Kuriyama S, Yoshikawa M, Ishizaka S, et al. A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector, Cell Struct Funct. 1991;16(6):503-510.
61. Kuriyama S, Sakamoto T, Masui K, et al. Tissue-specific expression of HSV-tk gene can induce efficient antitumor effect and protective immunity to wild-type hepatocellular carcinoma. Int J Cancer. 1997;71(3):470-475.
62. Cao G, Kuriyama S, Du P, et al. Construction of retroviral vectors to induce strong hepatoma cell-specific expression of cytokine genes. J Gastroenterol Hepatol. 1996;11(11):1053-1061.
63. Cao G, Kuriyama S, Du P, et al. Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor alpha gene transfer. Gastroenterology. 1997;112(2):501-510.
64. Su H, Chang JC, Xu SM, Kan YW. Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther. 1996;7(4):463-470.
65. Su H, Lu R, Chang JC, Kan YW. Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adeno-associated virus inhibits the growth of human hepatocellular carcinoma in athymic mice. Proc Natl Acad Sci USA. 1997;94(25):13891-13896.
66. Miyatake SI, Tani S, Feigenbaum F, et al. Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther. 1999;6(4):564-572.
67. Strayer MS, Guttentag SH, Ballard PL. Targeting type II and Clara cells for adenovirus-mediated gene transfer using the surfactant protein B promoter. Am J Respir Cell Mol Biol. 1998;18(1):1-11.
68. Doronin K, Kuppuswamy M, Toth K, et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol. 2001;75(7):3314-3324.
69. Zeiger MA, Takiyama Y, Bishop JO, Ellison AR, Saji M, Levine MA. Adenoviral infection of thyroid cells: a rationale for gene therapy for metastatic thyroid carcinoma. Surgery. 1996;120(6):921-925.
70. Braiden V, Nagayama Y, Iitaka M, Namba H, Niwa M, Yamashita S. Retrovirus-mediated suicide gene/prodrug therapy targeting thyroid carcinoma using a thyroid-specific promoter. Endocrinology. 1998;139(9):3996-3999.
71. Zhang R, Straus FH, DeGroot LJ, Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity. Thyroid. 2001;11(2):115-123.
72. Shimura H, Suzuki H, Miyazaki A, et al. Transcriptional activation of the thyroglobulin promoter directing suicide gene expression by thyroid transcription factor-1 in thyroid cancer cells. Cancer Res. 2001;61(9):3640-3646.
73. Blackwood L, O'Shaughnessy PJ, Reid SW, Argyle DJ. E. coli nitroreductase/CB1954: in vitro studies into a potential system for feline cancer gene therapy. Vet J. 2001;161(3):269-279.
74. Selvakumaran M, Bao R, Crijns AP, Connolly DC, Weinstein JK, Hamilton TC. Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element. Cancer Res. 2001;61(4):1291-1295.
75. Bao R, Selvakumaran M, Hamilton TC. Targeted gene therapy of ovarian cancer using an ovarian-specific promoter. Gynecol Oncol. 2002;84(2):228-234.
76. Yoshimura I, Suzuki S, Tadakuma T, Hayakawa M. Suicide gene therapy on LNCaP human prostate cancer cells. Int J Urol. 2001;8(7):S5-S8.
77. Xie X, Zhao X, Liu Y, et al. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. Cancer Res. 2001;61(18):6795-6804.
78. Harrington KJ, Linardakis E, Vile RG. Transcriptional control: an essential component of cancer gene therapy strategies? Adv Drug Deliv Rev. 2000;44(2-3):167-184.
79. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266(5193):2011-2015.
80. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA. 1995;92(20):9082-9086.
81. Tahara H, Yasui W, Tahara E, et al. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene. 1999;18(8):1561-1567.
82. Shay JW, Wright WE. Ageing and cancer: the telomere and telomerase connection. Novartis Found Symp. 2001;235:116-125.
83. Pan CX, Koeneman KS. A novel tumor-specific gene therapy for bladder cancer. Med Hypotheses. 1999;53(2):130-135.
84. Abdul-Ghani R, Ohana P, Matouk I, et al. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol Ther. 2000;2(6):539-544.
85. Boyd M, Mairs RJ, Mairs SC, et al. Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill. Oncogene. 2001;20(53):7804-7808.
86. Komata T, Koga S, Hirohata S, et al. A novel treatment of human malignant gliomas in vitro and in vivo: FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter. Int J Oncol. 2001;19(5):1015-1020.
87. Koga S, Hirohata S, Kondo Y, et al. FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo. Anticancer Res. 2001;21(3B):1937-1943.
88. Komata T, Kondo Y, Kanzawa T, et al. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res. 2001;61(15):5796-5802.
89. Gu J, Andreeff M, Roth JA, Fang B. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther. 2002;9(1):30-37.
90. Gu J, Kagawa S, Takakura M, et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res. 2000;60(19):5359-5364.
91. Plumb JA, Bilsland A, Kakani R, et al. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene. 2001;20(53):7797-7803.
92. Richards CA, Austin EA, Huber BE. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther. 1995;6(7):881-893.
93. Cao G, Kuriyama S, Gao J, et al. In vivo gene transfer of a suicide gene under the transcriptional control of the carcinoembryonic antigen promoter results in bone marrow transduction but can avoid bone marrow suppression. Int J Oncol. 1999;15(1):107-112.
94. Cao G, Kuriyama S, Gao J, et al. Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter. Gene Ther. 1999;6(1):83-90.
95. Osaki T, Tanio Y, Tachibana I, et al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 1994;54(20):5258-5261.
96. DiMaio JM, Clary BM, Via DF, Coveney E, Pappas TN, Lyerly HK. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery. 1994;116(2):205-213.
97. Tanaka T, Kanai F, Okabe S, et al. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res. 1996;56(6):1341-1345.
98. Brand K, Loser P, Arnold W, Bartels T, Strauss M. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach. Gene Ther. 1998;5(10):1363-1371.
99. Goto H, Osaki T, Kijima T, et al. Gene therapy utilizing the Cre/loxP system selectively suppresses tumor growth of disseminated carcinoembryonic antigen-producing cancer cells. Int J Cancer. 2001;94(3):414-419.
100. Koch PE, Guo ZS, Kagawa S, Gu J, Roth JA, Fang B. Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. Mol Ther. 2001;3(3):278-283.
101. Horimoto M, Sasaki Y, Ugawa S, et al. A novel strategy for cancer therapy by mutated mammalian degenerin gene transfer. Cancer Gene Ther. 2000;7(10):1341-1347.
102. Ueda K, Iwahashi M, Nakamori M, Nakamura M, Yamaue H, Tanimura H. Enhanced selective gene expression by adenovirus vector using Cre/loxP regulation system for human carcinoembryonic antigen-producing carcinoma Oncology. 2000;59(3):255-265.
103. Ueda K, Iwahashi M, Nakamori M, et al. Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the cre/loxP system in the orthotopic gastric carcinoma model. Cancer Res. 2001;61(16):6158-6162.
104. Kijima T, Osaki T, Nishino K, et al. Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer. Cancer Res. 1999;59(19):4906-4911.
105. Qiao J, Doubrovin M, Sauter BV, et al. Tumor-specific transcriptional targeting of suicide gene therapy. Gene Ther. 2002;9(3):168-175.
106. Ishikawa H, Nakata K, Mawatari F, et al. Utilization of variant-type of human alpha-fetoprotein promoter in gene therapy targeting for hepatocellular carcinoma. Gene Ther. 1999;6(4):465-470.
107. Ishikawa H, Nakata K, Mawatari F, et al. Retrovirus-mediated gene therapy for hepatocellular carcinoma with reversely oriented therapeutic gene expression regulated by alpha-fetoprotein enhancer/promoter. Biochem Biophys Res Commun. 2001;287(4):1034-1040.
108. Kanai F, Lan KH, Shiratori Y, et al. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res. 1997;57(3):461-465.
109. Bui LA, Butterfield LH, Kim JY, et al. In vivo therapy of hepatocellular carcinoma with a tumorspecific adenoviral vector expressing interleukin-2. Hum Gene Ther. 1997;8(18):2173-2182.
110. Cao G, Kuriyama S, Tsujinoue H, Chen Q, Mitoro A, Qi Z. A novel approach for inducing enhanced and selective transgene expression in hepatocellular-carcinoma cells. Int J Cancer. 2000;87(2):247-252.
111. Murayama Y, Tadakuma T, Kunitomi M, et al. Cell-specific expression of the diphtheria toxin A-chain coding sequence under the control of the upstream region of the human alpha-fetoprotein gene. J Surg Oncol. 1999;70(3):145-149.
112. Ohashi M, Kanai F, Tateishi K, et al. Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus. Biochem Biophys Res Commun. 2001;282(2):529-535.
113. Sato Y, Tanaka K, Lee G, et al. Enhanced and specific gene expression via tissue-specific production of Cre recombinase using adenovirus vector. Biochem Biophys Res Commun. 1998;244(2):455-462.
114. Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR. Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther. 1994;1(3):170-175.
115. Sikora K, Harris J, Hurst H, Lemoine N. Therapeutic strategies using c-erbB-2 promoter-controlled drug activation. Ann N Y Acad Sci. 1994;716:115-124; discussion 124-125, 140-143.
116. Stackhouse MA, Buchsbaum DJ, Kancharla SR, et al. Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors. Cancer Gene Ther. 1999;6(3):209-219.
117. Maeda T, O-Wang J, Matsubara H, et al. A minimum c-erbB-2 promoter-mediated expression of herpes simplex virus thymidine kinase gene confers selective cytotoxicity of human breast cancer cells to ganciclovir. Cancer Gene Ther. 2001;8(11):890-896.
118. Manome Y, Abe M, Hagen MF, Fine HA, Kufe DW. Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Res. 1994;54(20):5408-5413.
119. Chen L, Chen D, Manome Y, Dong Y, Fine HA, Kufe DW. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest. 1995;96(6):2775-2782.
120. Chen L, Pulsipher M, Chen D, et al. Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources. J Clin Invest. 1996;98(11):2539-2548.
121. Tai YT, Strobel T, Kufe D, Cannistra SA. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. Cancer Res. 1999;59(9):2121-2126.
122. Koeneman KS, Kao C, Ko SC, et al. Osteocalcindirected gene therapy for prostate-cancer bone metastasis. World J Urol. 2000;18(2):102-110.
123. Matsubara S, Wada Y, Gardner TA, et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res. 2001;61(16):6012-6019.
124. Benjamin R, Helman L, Meyers P, Reaman G. A phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung. Hum Gene Ther. 2001;12(12):1591-1593.
125. Shirakawa T, Ko SC, Gardner TA, et al. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy. Cancer Gene Ther. 1998;5(5):274-280
126. Yeung F, Law WK, Yeh CH, et al. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem. 2002;277(4):2468-2476.
127. Chung I, Schwartz PE, Crystal RG, Pizzorno G, Leavitt J, Deisseroth AB. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells. Cancer Gene Ther. 1999;6(2):99-106.
128. Peng XY, Won JH, Rutherford T, et al. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. Cancer Res. 2001;61(11):4405-4413.
129. Miyauchi M, Shimada H, Kadomatsu K, et al. Frequent expression of midkine gene in esophageal cancer suggests a potential usage of its promoter for suicide gene therapy. Jpn J Cancer Res. 1999;90(4):469-475.
130. Adachi Y, Reynolds PN, Yamamoto M, et al. Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors. Cancer Res. 2000;60(16):4305-4310.
131. Adachi Y, Matsubara S, Muramatsu T, Curiel DT, Reynolds PN. Midkine promoter-based adenoviral suicide gene therapy to midkine-positive pediatric tumor. J Pediatr Surg. 2002;37 (4):588-592.
132. Casado E, Gomez-Navarro J, Yamamoto M, et al. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin Cancer Res. 2001;7(8):2496-2504.
133. Wesseling JG, Yamamoto M, Adachi Y, et al. Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma. Cancer Gene Ther. 2001;8(12):990-996.
134. Majumdar AS, Hughes DE, Lichtsteiner SP, Wang Z, Lebkowski JS, Vasserot AP. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther. 2001;8(7):568-578.
135. Gu J, Andreeff M, Roth JA, Fang B. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther. 2002;9(1):30-37.
136. Komata T, Kanzawa T, Kondo Y, Kondo S. Telomerase as a therapeutic target for malignant gliomas. Oncogene. 2002;21(4):656-663.
137. Kyo S, Takakura M, Inoue M. Telomerase activity in cancer as a diagnostic and therapeutic target. Histol Histopathol. 2000;15(3):813-824.
138. Lan KH, Kanai F, Shiratori Y, et al. In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res. 1997;57(19):4279-4284.
139. Cao GW, Qi ZT, Pan X, et al. Gene therapy for human colorectal carcinoma using human CEA promoter contro led bacterial ADP-ribosylating toxin genes human CEA: PEA & DTA gene transfer. World J Gastroenterol. 1998;4(5):388-391.
140. Nishino K, Osaki T, Kumagai T, et al. Adenovirus-mediated gene therapy specific for small cell lung cancer cells using a Myc-Max binding motif. Int J Cancer. 2001;91(6):851-856.
141. Humphreys MJ, Ghaneh P, Greenhalf W, et al. Hepatic intra-arterial delivery of a retroviral vector expressing the cytosine deaminase gene, controlled by the CEA promoter and intraperitoneal treatment with 5-fluorocytosine suppresses growth of colorectal liver metastases. Gene Ther. 2001;8(16):1241-1247.
142. Tanaka S, Iwai M, Harada Y, et al. Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter. Cancer Gene Ther. 2000;7(9):1241-1250.
143. Nyati MK, Sreekumar A, Li S, et al. High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoter-enhancer. Cancer Res. 2002;62(8):2337-2342.
144. Tanaka T, Kanai F, Lan KH, et al. Adenovirus-mediated gene therapy of gastric carcinoma using cancer-specific gene expression in vivo. Biochem Biophys Res Commun. 1997;231(3):775-779.
145. Ido A, Uto H, Moriuchi A, et al. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Cancer Res. 2001;61(7):3016-3021.
146. Maxwell IH, Spitzer AL, Long CJ, Maxwell E Autonomous parvovirus transduction of a gene under control of tissue-specific or inducible promoters. Gene Ther. 1996;3(1):28-36.
147. Wills KN, Huang WM, Harris MP, Machemer T, Maneval DC, Gregory RJ. Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther. 1995;2(3):191-197.
148. Kaneko S, Hallenbeck P, Kotani T, et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 1995;55(22):5283-5287.
149. Ido A, Nakata K, Kato Y, et al. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res. 1995;55(14):3105-3109.
150. Hernandez-Alcoceba R, Pihalja M, Nunez G, Clarke MF. Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells. Cancer Gene Ther. 2001;8(4):298-307.
151. Takakuwa K, Fujita K, Kikuchi A, et al. Direct intratumoral gene transfer of the herpes simplex virus thymidine kinase gene with DNA-liposome complexes: growth inhibition of tumors and lack of localization in normal tissues. Jpn J Cancer Res. 1997;88(2):166-175.
152. Zheng S, Wang S, Ma L, Sun K. HER2 promoter controlled specific expression of the reporter gene in ovarian cancer cell line [in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2000;17(5):313-315.
153. Patterson A, Harris AL. Molecular chemotherapy for breast cancer. Drugs Aging. 1999;14(2):75-90.
154. Zaretsky JZ, Sarid R, Aylon Y, Mittelman LA, Wreschner DH, Keydar I. Analysis of the promoter of the MUC1 gene overexpressed in breast cancer. FEBS Lett. 1999;461(3):189-195.
155. Ko SC, Cheon J, Kao C, et al. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res. 1996;56(20):4614-4619.
156. Cheon J, Ko SC, Gardner TA, et al. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cancer Gene Ther. 1997;4(6):359-365.
157. Robertson MW 3rd, Wang M, Siegal GP, et al. Use of a tissue-specific promoter for targeted expression of the herpes simplex virus thymidine kinase gene in cervical carcinoma cells. Cancer Gene Ther. 1998;5(5):331-336.
158. Garver RI Jr, Goldsmith KT, Rodu B, Hu PC, Sorscher EJ, Curiel DT. Strategy for achieving selective killing of carcinomas. Gene Ther. 1994;1 (1):46-50.
159. Anderson LM, Krotz S, Weitzman SA,Thimmapaya B. Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach. Cancer Gene Ther. 2000;7(6):845-852.
160. Kumagai T, Tanio Y, Osaki T, et al. Eradication of Myc-overexpressing small cell lung cancer cells transfected with herpes simplex virus thymidine kinase gene containing Myc-Max response elements. Cancer Res. 1996;56(2):354-358.
161. Sugaya S, Fujita K, Kikuchi A, et al. Inhibition of tumor growth by direct intratumoral gene transfer of herpes simplex virus thymidine kinase gene with DNA-liposome complexes. Hum Gene Ther. 1996;7(2):223-230.
162. Lung RW, Lee KA. The cellular oncogene EWS/ activating transcription factor 1 is unable to activate adenovirus-borne promoters: implications for cytotoxic prodrug therapy of malignant melanoma of soft parts. Cancer Gene Ther. 2000;7(3):396-406.
163. Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther. 2001;3(3):385-394.
164. Iyengar RV, Pawlik CA, Krull EJ, et al. Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression. Cancer Res. 2001;61(7):3045-3052.
165. McLaughlin PM, Harmsen MC, Dokter WH, et al. The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy. Cancer Res. 2001;61 (10):4105-4111.
166. Nawrath M, Pavlovic J, Moelling K. Inhibition of human hematopoietic tumor formation by targeting a repressor Myb-KRAB to DNA. Cancer Gene Ther. 2000;7(6):963-972.
167. Inase N, Horita K, Tanaka M, Miyake S, Ichioka M, Yoshizawa Y. Use of gastrin-releasing peptide promoter for specific expression of thymidine kinase gene in small-cell lung carcinoma cells. Int J Cancer. 2000;85(5):716-719.
168. Morimoto E, Inase N, Mlyake S, Yoshizawa Y. Adenovirus-mediated suicide gene transfer to small cell lung carcinoma using a tumor-specific promoter. Anticancer Res. 2001;21(1A):329-331.
169. Vandier D, Calvez V, Massade L, et al. Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: a specific gene therapy strategy. J Natl Cancer Inst. 2000;92(8):642-647.
170. Yamamura H, Hashio M, Noguchi M, et al. Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res. 2001;61 (10):3969-3977.
171. Ohana P, Bibi O, Matouk I, et al. Use of H19 regulatory sequences for targeted gene therapy in cancer. Int J Cancer. 2002;98(5):645-650.
172. Chen RH, McCormick F. Selective targeting to the hyperactive beta-catenin/T-cell factor pathway in colon cancer cells. Cancer Res. 2001;61(11):4445-4449.
173. Lipinski KS, Djeha AH, Krausz E, et al. Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53. Gene Ther. 2001;8(4):274-281.
174. Inase N, Miyake S, Yoshizawa Y. Calretinin promoter for suicide gene expression in malignant mesothelioma. Anticancer Res. 2001;21(2A):1111-1114.
175. Messina M, Yu DM, Learoyd DL, Both GW, Molloy PL, Robinson BG. High level, tissue-specific expression of a modified calcitonin/calcitonin gene-related peptide promoter in a human medullary thyroid carcinoma cell line. Mol Cell Endocrinol. 2000;164(1-2):219-224.
176. Minemura K, Takeda T, Minemura K, et al. Cell-specific induction of sensitivity to ganciclovir in medullary thyroid carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Endocrinology. 2000;141(5):1814-1822.
177. Yamazaki M, Zhang R, Straus FH, et al. Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12. Gene Ther. 2002;9(1):64-74.
178. Nettelbeck DM, Zwicker J, Lucibello FC, et al. Cell cycle regulated promoters for the targeting of tumor endothelium. Adv Exp Med Biol. 1998;451:437-440.
179. Nettelbeck DM, Jerome V, Muller R. A dual specificity promoter system combining cell cycle-regulated and tissue-specific transcriptional control. Gene Ther. 1999;6(7):1276-1281.
180. Velasco B, Ramirez JR, Relloso M, et al. Vascular gene transfer driven by endoglin and ICAM-2 endothelial-specific promoters. Gene Ther. 2001;8(12):897-904.
181. Werner H, Shalita-Chesner M, Abramovitch S, Idelman G, Shaharabani-Gargir L, Glaser T. Regulation of the insulin-like growth factor-I receptor gene by oncogenes and antioncogenes: implications in human cancer. Mol Genet Metab. 2000;71(1-2):315-320.
182. Parr MJ, Manome Y, Tanaka T, et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med. 1997;3(10):1145-1149.
183. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93(4):266-276.
184. Jaggar RT, Chan HY, Harris AL, Bicknell R. Endothelial cell-specific expression of tumor necrosis factor-alpha from the KDR of E-selectin promoters following retroviral delivery. Hum Gene Ther. 1997;8(18):2239-2247.
185. Szary J, Kalita K, Przybyszewska M, et al. KDR promoter can transcriptionally target cytosine deaminase suicide gene to cancer cells of non-endothelial origin. Anticancer Res. 2001;21(5):3471-3475.
186. Modlich U, Pugh CW, Bicknell R. Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Ther. 2000;7(10):896-902.
187. Heidenreich R, Kappel A, Breier G. Tumor endothelium-specific transgene expression directed by vascular endothelial growth factor receptor-2 (Flk1) promoter/enhancer sequences. Cancer Res. 2000;60(21):6142-6147.
188. Bauerschmitz GJ, Nettelbeck DM, Kanerva A, et al. The flt-1 promoter for transcriptional targeting of teratocarcinoma. Cancer Res. 2002;62(5):1271-1274.
189. Walton T, Wang JL, Ribas A, Barsky SH, Economou J, Nguyen M. Endothelium-specific expression of an E-selectin promoter recombinant adenoviral vector. Anticancer Res. 1998;18(3A):1357-1360.
190. Ozaki K, Yoshida T, Ide H, et al. Use of von Willebrand factor promoter to transduce suicidal gene to human endothelial cells, HUVEC. Hum Gene Ther. 1996;7(13):1483-1490.
191. Jager U, Zhao Y, Porter CD. Endothelial cell-specific transcriptional targeting from a hybrid long terminal repeat retrovirus vector containing human prepro-endothelin-1 promoter sequences. J Virol. 1999;73(12):9702-9709.
192. Mavria G, Jager U, Porter CD. Generation of a high titre retroviral vector for endothelial cell-specific gene expression in vivo. Gene Ther. 2000;7(5):368-376.
193. Varda-Bloom N, Shaish A, Gonen A, et al. Tissue-specific gene therapy directed to tumor angiogenesis. Gene Ther. 2001;8(11):819-827.
194. Shibata T, Akiyama N, Noda M, Sasai K, Hiraoka M. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. Int J Radiat Oncol Biol Phys. 1998;42(4):913-916.
195. Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther. 2000;7(6):493-498.
196. Shibata T, Giaccia AJ, Brown JM. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia. 2002;4(1):40-48.
197. Koshikawa N, Takenaga K, Tagawa M, Sakiyama S. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res. 2000;60(11):2936-2941.
198. Ruan H, Su H, Hu L, Lamborn KR, Kan YW, Deen DF. A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy. Neoplasia. 2001;3(3):255-263.
199. Dachs GU, Patterson AV, Firth JD, et al. Targeting gene expression to hypoxic tumor cells. Nat Med. 1997;3(5):515-520.
200. Little E, Ramakrishnan M, Roy B, Gazit G, Lee AS. The glucose-regulated proteins (GRP78 and GRP94): functions, gene regulation, and applications. Crit Rev Eukaryot Gene Expr. 1994;4(1):1-18.
201. Gazit G, Kane SE, Nichols P, Lee AS. Use of the stress-inducible grp78/BiP promoter in targeting high level gene expression in fibrosarcoma in vivo. Cancer Res. 1995;55(8):1660-1663.
202. Gazit G, Hung G, Chen X, Anderson WF, Lee AS. Use of the glucose starvation-inducible glucose-regulated protein 78 promoter in suicide gene therapy of murine fibrosarcoma. Cancer Res. 1999;59(13):3100-3106.
203. Chen X, Zhang D, Dennert G, Hung G, Lee AS. Eradication of murine mammary adenocarcinoma through HSVtk expression directed by the glucose-starvation inducible grp78 promoter. Breast Cancer Res Treat. 2000;59(1):81-90.
204. Luna MC, Chen X, Wong S, et al. Enhanced photodynamic therapy efficacy with inducible suicide gene therapy controlled by the grp promoter. Cancer Res. 2002;62 (5):1458-1461.
205. Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci. 2001;26(8):504-510.
206. Katabi MM, Chan HL, Karp SE, Batist G. Hexokinase type II: a novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells. Hum Gene Ther. 1999;10(2):155-164.
207. Harats D, Kurihara H, Belloni P, et al. Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter. J Clin Invest. 1995;95(3):1335-1344.
208. Nettelbeck DM, Jerome V, Muller R. A strategy for enhancing the transcriptional activity of weak cell type-specific promoters. Gene Ther. 1998;5(12):1656-1664.
209. Marples B, Greco O, Joiner MC, Scott SD. Molecular approaches to chemo-radiotherapy. Eur J Cancer. 2002;38(2):231-239.
210. Kawashita Y, Ohtsuru A, Kaneda Y, et al. Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation. Hum Gene Ther. 1999;10(9):1509-1519.
211. Manome Y, Kunieda T, Wen PY, Koga T, Kufe DW, Ohno T. Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum Gene Ther. 1998;9(10):1409-1417.
212. Seung LP, Mauceri HJ, Beckett MA, Hallahan DE, Hellman S, Weichselbaum RR. Genetic radiotherapy overcomes tumor resistance to cytotoxic agents. Cancer Res. 1995;55(23):5561-5565.
213. Weichselbaum RR, Hallahan DE, Beckett MA, et al. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res. 1994;54(16):4266-4269.
214. Mauceri HJ, Hanna NN, Wayne JD, Hallahan DE, Hellman S, Weichselbaum RR. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res. 1996;56(19):4311-4314.
215. Mauceri HJ, Seung LP, Grdina WL, Swedberg KA, Weichselbaum RR. Increased injection number enhances adenoviral genetic radiotherapy. Radiat Oncol Investig. 1997;5(5):220-226.
216. Hallahan DE, Mauceri HJ, Seung LP, et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med. 1995;1(8):786-791.
217. Hallahan DE, Qu S, Geng L, et al. Radiation-mediated control of drug delivery. Am J Clin Oncol. 2001;24(5):473-480.
218. Weichselbaum RR, Kufe DW, Advani SJ, Roizman B. Molecular targeting of gene therapy and radiotherapy. Acta Oncol. 2001;40(6):735-738.
219. Scott SD, Marples B, Hendry JH, et al. A radiation-controlled molecular switch for use in gene therapy of cancer. Gene Ther. 2000;7(13):1121-1125.
220. Hanna NN, Hallahan DE, Wayne JD, Weischselbaum RR. Modification of the radiation response by the administration of exogenous genes. Semin Radiat Oncol. 1996;6(4):321-328.
221. Kaminski JM, Kaminski RJ, Dicker AP, Urbain JL. Defining a future role for radiogenic therapy. Cancer Treat Rev. 2001;27(5):289-294.
222. Worthington J, Robson T, Murray M, O'Rourke M, Keilty G, Hirst DG. Modification of vascular tone using iNOS under the control of a radiation-inducible promoter. Gene Ther. 2000;7(13):1126-1131.
223. Worthington J, Robson T, O'Keeffe M, Hirst DG. Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy. Gene Ther. 2002;9(4):263-269.
224. Nuyts S, Van Mellaert L, Theys J, et al. Radio-responsive recA promoter significantly increases TNFalpha production in recombinant clostridia after 2 Gy irradiation. Gene Ther. 2001;8(15):1197-1201.
225. Nuyts S, Van Mellaert L, Theys J, Landuyt W, Lambin P, Anne J. The use of radiation-induced bacterial promoters in anaerobic conditions: a means to control gene expression in clostridium-mediated therapy for cancer. Radiat Res. 2001;155(5):716-723.
226. Ueda T, Akiyama N, Sai H, et al. c-IAP2 is induced by ionizing radiation through NF-kappaB binding sites. FEBS Lett. 2001;491(1-2):40-44.
227. Madio DP, van Gelderen P, DesPres D, et al. On the feasibility of MRI-guided focused ultrasound for local induction of gene expression. J Magn Reson Imaging. 1998;8(1):101-104.
228. Braiden V, Ohtsuru A, Kawashita Y, et al. Eradication of breast cancer xenografts by hyperthermic suicide gene therapy under the control of the heat shock protein promoter. Hum Gene Ther. 2000;11(18):2453-2463.
229. Lee YJ, Galoforo SS, Battle P, Lee H, Corry PM, Jessup JM. Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy. Cancer Gene Ther. 2001;8(6):397-404.
230. Lohr F, Hu K, Huang Q, et al. Enhancement of radiotherapy by hyperthermia-regulated gene therapy. Int J Radiat Oncol Biol Phys. 2000;48(5):1513-1518.
231. Lohr F, Huang Q, Hu K, Dewhirst MW, Li CY. Systemic vector leakage and transgene expression by intratumorally injected recombinant adenovirus vectors. Clin Cancer Res. 2001;7(11):3625-3628.
232. Brade AM, Ngo D, Szmitko P, Li PX, Liu FF, Klamut HJ. Heat-directed gene targeting of adenoviral vectors to tumor cells. Cancer Gene Ther. 2000;7(12):1566-1574.
233. Huang Q, Hu JK, Lohr F, et al. Heat-induced gene expression as a novel targeted cancer gene therapy strategy. Cancer Res. 2000;60(13):3435-3439.
234. Vekris A, Maurange C, Moonen C, et al. Control of transgene expression using local hyperthermia in combination with a heat-sensitive promoter. J Gene Med. 2000;2(2):89-96.
235. Ito A, Shinkai M, Honda H, Kobayashi T. Heat-inducible TNF-alpha gene therapy combined with hyperthermia using magnetic nanoparticles as a novel tumor-targeted therapy. Cancer Gene Ther. 2001;8(9):649-654.
236. Walther W, Stein U, Fichtner I, Alexander M, Shoemaker RH, Schlag PM. Mdrl promoter-driven tumor necrosis factor-alpha expression for a chemotherapy-controllable combined in vivo gene therapy and chemotherapy of tumors. Cancer Gene Ther. 2000;7(6):893-900.
237. Walther W, Stein U, Schlag PM. Use of the human MDR1 promoter for heat-inducible expression of therapeutic genes. Int J Cancer. 2002;98(2):291-296.
238. Walther W, Stein U, Fichtner I, et al. In vivo evaluation of a drug-inducible vector system for the combined gene- and chemotherapy of cancer. Adv Exp Med Biol. 1998;451:139-144.
239. Patil R, Chavez JB, Yee D. Inducible expression of herpes simplex virus thymidine kinase increases sensitivity to ganciclovir but does not enhance by-stander effect in breast cancer cells. Breast Cancer Res Treat. 2000;62(2):109-115.
240. Pitzer C, Schindowski K, Pomer S, Wirth T, Zoller M. In vivo manipulation of interleukin-2 expression by a retroviral tetracycline (tet)-regulated system. Cancer Gene Ther. 1999;6(2):139-146.
241. Yu JS, Sena-Esteves M, Paulus W, Breakefield XO, Reeves SA. Retroviral delivery and tetracycline-dependent expression of IL-1beta-converting enzyme (ICE) in a rat glioma model provides controlled induction of apoptotic death in tumor cells. Cancer Res. 1996;56(23):5423-5427.
242. Rubinchik S, Wang D, Yu H, et al. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression. Mol Ther. 2001;4(5):416-426.
243. Iida A, Chen ST, Friedmann T, Yee JK. Inducible gene expression by retrovirus-mediated transfer of a modified tetracycline-regulated system. J Virol. 1996;70(9):6054-6059.
244. Baasner S, von Melchner H, Klenner T, Hilgard P, Beckers T. Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase. Oncogene. 1996;13(5):901-911.
245. Paulus W, Baur I, Oberer DM, Breakefield XO, Reeves SA. Regulated expression of the diphtheria toxin A gene in human glioma cells using prokaryotic transcriptional control elements. J Neurosurg. 1997;87(1):89-95.
246. Yao F, Svensjo T, Winkler T, Lu M, Eriksson C, Eriksson E. Tetracycline repressor, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells. Hum Gene Ther. 1998;9(13):1939-1950.
247. Giavazzi R, Giuliani R, Coltrini D, et al. Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors. Cancer Res. 2001;61(1):309-317.
248. Chong H, Ruchatz A, Clackson T, Rivera VM, Vile RG. A system for small-molecule control of conditionally replication-competent adenoviral vectors. Mol Ther. 2002;5(2):195-203.
249. Hernandez-Alcoceba R, Pihalja M, Wicha MS, Clarke MF. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors. Hum Gene Ther. 2000;11(14):2009-2024.
250. Tannour-Louet M, Porteu A, Vaulont S, Kahn A, Vasseur-Cognet M. A tamoxifen-inducible chimeric Cre recombinase specifically effective in the fetal and adult mouse liver. Hepatology. 2002;35(5):1072-1081.
251. Datta R, Taneja N, Sukhatme VP, Qureshi SA, Weichselbaum R, Kufe DW. Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci USA. 1993;90(6):2419-2422.
252. Joki T, Nakamura M, Ohno T. Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir. Hum Gene Ther. 1995;6(12):1507-1513.
253. Marples B, Scott SD, Hendry JH, Embleton MJ, Lashford LS, Margison GP. Development of synthetic promoters for radiation-mediated gene therapy. Gene Ther. 2000;7(6):511-517.
254. Yook JI, Kim J. Expression of p21WAF1/CIP1 is unrelated to p53 tumour suppressor gene status in oral squamous cell carcinomas. Oral Oncol. 1998;34(3):198-203.
255. Codegoni AM, Nicoletti MI, Buraggi G, et al. Molecular characterisation of a panel of human ovarian carcinoma xenografts. Eur J Cancer. 1998;34(9):1432-1438.
256. Clasen S, Schulz WA, Gerharz CD, Grimm MO, Christoph F, Schmitz-Drager BJ. Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma. Br J Cancer. 1998;77(4):515-521.
257. Sourvinos G, Spandidos DA. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. Biochem Biophys Res Commun. 1998;245(1):75-80.
258. Wasylyk C, Salvi R, Argentini M, et al. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene. 1999;18(11):1921-1934.
259. Schwerer MJ, Sailer A, Kraft K, Baczako K, Maier H. Patterns of p21(waf1/cip1) expression in non-papillomatous nasal mucosa, endophytic sinonasal papillomas, and associated carcinomas. J Clin Pathol. 2001;54(11):871-876.
260. Biankin AV, Kench JG, Morey AL, et al. Over-expression of p21 (WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res. 2001;61(24):8830-8837.
261. O'Hanlon DM, Kiely M, MacConmara M, et al. An immunohistochemical study of p21 and p53 expression in primary node-positive breast carcinoma. Eur J Surg Oncol. 2002;28(2):103-107.
262. Vidal MJ, Loganzo F Jr, de Oliveira AR, Hayward NK, Albino AP. Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. Melanoma Res. 1995;5(4):243-250.
263. Karjalainen JM, Eskelinen MJ, Kellokoski JK, Reinikainen M, Alhava EM, Kosma VM. p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival. Br J Cancer. 1999;79(5-6):895-902.
264. Patterson LH, McKeown SR, Robson T, Gallagher R, Raleigh SM, Orr S. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des. 1999;14(6):473-486.
265. McCarthy HO, Yakkundi A, McErlane V, et al. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther. 2003;10(1):40-48.
266. Nuyts S, Van Mellaert L, Theys J, Landuyt W, Lambin P, Anne J. Clostridium spores for tumor-specific drug delivery. Anticancer Drugs. 2002;13(2):115-125.
267. Nielsen OS, Horsman M, Overgaard J. A future for hyperthermia in cancer treatment? Eur J Cancer. 2001;37(13):1587-1589.
268. Arai Y, Kubo T, Kobayashi K, et al. Control of delivered gene expression in chondrocytes using heat shock protein 70B promoter. J Rheumatol. 1999;26(8):1769-1774.
269. Lin H, Blank M, Rossol-Haseroth K, Goodman R. Regulating genes with electromagnetic response elements. J Cell Biochem. 2001;81(1):143-148.
270. Stein U, Walther W, Shoemaker RH. Vincristine induction of mutant and wild-type human multidrug-resistance promoters is cell-type-specific and dose-dependent. J Cancer Res Clin Oncol. 1996;122(5):275-282.
271. Walther W, Wendt J, Stein U. Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy. Gene Ther. 1997;4(6):544-552.
272. Zhang L, Adams JY, Billick E, et al. Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer. Mol Ther. 2002;5(3):223-232.
273. Lee EJ, Jameson JL. Cell-specific Cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy. Hum Gene Ther. 2002;13(4):533-542.
274. Yoshimura I, Suzuki S, Hayakawa M. Application of Cre-loxP system to the urinary tract and cancer gene therapy. Mol Urol. 2001;5 (2):81-84.
275. Iyer M, Wu L, Carey M, Wang Y, Smallwood A, Gambhir SS. Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci USA. 2001;98(25):14595-14600.
276. Jounaidi Y, Waxman DJ. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res. 2000;60(14):3761-3769.
277. Putzer BM, Stiewe T, Crespo F, Esche H. Improved safety through tamoxifen-regulated induction of cytotoxic genes delivered by Ad vectors for cancer gene therapy. Gene Ther. 2000;7(15):1317-1325.